Search clinical trials for: Cabazitaxel

Total 132 results

Institut Bergonié
Sanofi; GECEM

Completed

Consensus Method to Evaluate the Conformity of Prescription of a Chemotherapy (CABOBS)

Prostate Cancer
Institute of Cancer Research, United Kingdom
Sanofi; Janssen, LP; Menarini Group; University of Twente; Prostate Cancer UK

Terminated

Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer (CTC-STOP)

Adenocarcinoma of the Prostate

United Kingdom
University Hospitals Bristol and Weston NHS Foundation...
Sanofi

Unknown

Bristol Bladder Trial

Infiltrating Bladder Urothelial Carcinoma

United Kingdom
University of Alabama at Birmingham
Sanofi; Astellas Pharma Inc

Withdrawn

Phase I Trial of PACE for Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States
Vejle Hospital

Completed

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. (CaTo-ROC)

Ovarian Cancer

Denmark
Eisai Inc.
Purdue Pharma LP

Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Insomnia Disorders

Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
Maryland Technology Development Corporation

Terminated

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Prostate Cancer

United States
Hellenic Cooperative Oncology Group
Sanofi

Completed

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer (CABA-BONE)

Bone Metastatic Prostate Cancer

Greece
Centro Nacional de Investigaciones Oncologicas...

Unknown

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. (PROSTAC)

Advanced Prostate Cancer | Docetaxel | Cabazitaxel

Spain
University Hospital, Clermont-Ferrand

Unknown

Effect of the Quality of Dietary Proteins on the Sleep Young Elite Athletes and the Obese Adolescent (Protmorpheus)

Obese Adolescent | Elite Adolescent Athletes

France
Marc Sakwa, MD
Essential Pharmaceuticals, LLC

Completed

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

Myocardial Ischemia | Heart Diseases | Coronary Artery Disease | Coronary Disease | Valvular Heart Disease

United States
Sanofi

Terminated

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (PRIMCAB)

Prostate Cancer Metastatic

Canada, United States
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
howard safran
The Miriam Hospital; Rhode Island Hospital; Roger Williams Medical Center

Terminated

Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

Gastric Cancer | Gastrooesophageal Cancer | Esophageal

United States
The Rogosin Institute

Completed

Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

Prostate Cancer

United States
Dr Anjali Zarkar
Sanofi

Completed

Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel (CabB1)

Transitional Cell Carcinoma

United Kingdom
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Medical University of South Carolina
Peregrine Pharmaceuticals

Terminated

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

United States
University of Colorado, Denver
Janssen Services, LLC

Terminated

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Terminated

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Metastatic Castration Resistant Prostate Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

Germany
Azienda Socio Sanitaria Territoriale degli Spedali...
San Luigi Gonzaga Hospital

Unknown

Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines (CabACC)

Adrenocortical Carcinoma

Italy
Weill Medical College of Cornell University
Sanofi

Completed

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Adenocarcinoma | Distal Esophageal Adenocarcinoma

United States
AIO-Studien-gGmbH
Sanofi; ClinAssess GmbH

Terminated

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

Breast Cancer | Lung Cancer | Recurrent Brain Metastases | Progressive Brain Metastases

Germany
M.D. Anderson Cancer Center
Sanofi

Withdrawn

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

Brain Cancer
Consorzio Oncotech

Unknown

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Prostate Cancer | Castration-resistant Prostate Cancer

Italy
British Columbia Cancer Agency
Sanofi; Ozmosis Research Inc.

Unknown

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer

Canada, Australia
Sidney Kimmel Cancer Center at Thomas Jefferson...
Sanofi

Completed

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Urothelial Carcinoma

United States
Sanofi

Completed

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (TAXYNERGY)

Prostate Cancer Metastatic

United States, Canada
University of Ulm

Completed

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) WHO Grade IV

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Malignant Neoplasm

United States
Gustave Roussy, Cancer Campus, Grand Paris
Sanofi

Unknown

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer (CABA-DOC)

Metastatic Castration-resistant Prostate Cancer

France
German Breast Group

Completed

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Primary Breast Cancer

Germany
Hellenic Cooperative Oncology Group
Sanofi

Completed

Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

Breast Cancer

Greece
Rahul Aggarwal
Sanofi

Completed

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Spanish Oncology Genito-Urinary Group

Completed

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Hormone Refractory Prostate Cancer

Spain
SCRI Development Innovations, LLC
Sanofi; GlaxoSmithKline; Novartis

Terminated

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Metastatic Breast Cancer With Intracranial Metastases

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RACATREX)

Squamous Cell Carcinoma of the Head and Neck

Belgium, Luxembourg
University of Alabama at Birmingham
Sanofi

Completed

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLC

United States
Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
Sanofi

Completed

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA)

Prostate Cancer

Korea, Republic of, Spain, United States, Argentina, Peru, Romania, Taiwan, United Kingdom, Belgium, Chile, Netherlands, Australia, Germany, Tunisia, Brazil, Canada, France, Hungary, Poland, Russian Federation, South Africa, Turkey
Sanofi

Completed

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (PEGAZUS)

Prostate Cancer

Japan
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Achieve Life Sciences

Completed

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

Prostate Cancer

France, United States, Canada, Australia, Hungary, Czech Republic, Russian Federation, United Kingdom
Merrimack Pharmaceuticals
Sanofi

Completed

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Solid Tumors

France, United States
RWTH Aachen University

Terminated

Neoadjuvant Chemotherapy With Cabazitaxel (CLUBNET)

High-Risk Cancer

Germany
Erasmus Medical Center
Sanofi

Withdrawn

Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs (CARVE)

Prostatic Neoplasms

Netherlands
Sanofi

Completed

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Malignant Solid Tumor - Malignant Nervous System Neoplasm

United States, Canada
Sanofi

Completed

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

France, United Kingdom, United States

3

Subscribe